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Abstract 
Background: With increasing emphasis on pragmatic trials, new randomized clinical trial 
GHVLJQVDUHEHLQJSURSRVHGWRHQKDQFHWKHµUHDOZRUOG¶QDWXUHRIWKHGDWDJHQHUDWHG:HGHVFULEH
one such design (when unmasked trials using usual care controls are acceptable) called Trials 
within Cohorts that is increasingly used in various countries because of its efficiency in 
recruitment, advantages in reducing subject burden, and ability to better mimic real world 
consent processes. 
Methods: Descriptive, ethical, and U.S. regulatory analysis of the Trials within Cohort design. 
Results:  Trials within Cohorts design involves, after recruitment into a cohort, randomization of 
eligible subjects, followed by an asymmetric treatment of the two arms: those selected for the 
experimental arm provide informed consent for the intervention trial while the data from the 
control arm are used based on prior broad permission. Thus, unlike the traditional Zelen post-
randomization consent design, the cohort participants are informed about future research within 
the cohort; however, the extent of this disclosure currently varies among studies. Thus, ethical 
analysis is provided for two types of situations: when the pre-randomization disclosure and 
consent regarding the embedded trials are fairly explicit and detailed versus when they consist of 
only general statements about future data use. These differing ethical situations could have 
implications for how ethics review committees apply U.S. research rules regarding waivers and 
alterations of informed consent. 
Conclusions:  Trials within Cohorts is a promising new pragmatic RCT design that is being 
increasingly used in various countries. Although the asymmetric consent procedures for the 
experimental versus control arm subjects can initially raise ethical concerns, it is ethically 
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superior to previous post-randomization consent designs and can have important advantages over 
traditional trial designs. 
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 There is increasing recognition of the value of pragmatic clinical trials, especially as it 
relates to the vision of a learning healthcare system that aims to closely integrate the delivery of 
medical services with clinical research. In such a system, the generation of knowledge would be 
³HPEHGGHGLQWRWKHFRUHRIWKHSUDFWLFHRIPHGLFLQH´OHDGLQJWR³FRQWLQXDOLPSURYHPHQWLQ
FDUH´(1) The advent of a modern electronic health record system makes it feasible and relatively 
inexpensive to conduct studies in the context of routine clinical practice.(2)  Such a vision 
provides an opportunity to think creatively about novel trial designs that can fulfill this pragmatic 
imperative.   
,QWKLVSDSHUZHGHVFULEHDQHPHUJLQJSUDJPDWLFWULDOSDUDGLJPFDOOHGµ7ULDOVZLWKLQ
&RKRUWV¶7ZL&Vwhich involves longitudinal cohort studies that provide a platform for 
randomized clinical trials. To date, studies using the design have obtained research ethics 
committee approval in 10 countries (Australia, Canada, Finland, France, Germany, Mexico, 
Netherlands, Spain, UK and the USA) with the most growth in the UK,(3-7) Canada,(8-11) and 
the Netherlands.(12)  The rare disease SPIN (Scleroderma Patient-centered Intervention 
Network) cohort has obtained IRB approval to recruit to its cohort and conduct four intervention 
trials using the design in the US, Canada, Mexico, France and Spain.(10) 
We first describe the features of TwiCs, and their strengths and limitations as a pragmatic 
randomized controlled trial (RCT) design. Because the TwiCs design is novel and unfamiliar to 
most research ethics committees/institutional review boards²and also because it involves an 
element of post-randomization consent which has a history of controversy(13)²we largely focus 
on the ethical issues in conducting TwiCs. We place TwiCs within a brief history of RCTs that 
obtain informed consent after randomization and then provide an ethical analysis of TwiCs, 
including a discussion of how it might be regulated by US institutional review boards. 
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Trials within Cohorts  
Randomised controlled trials remain the gold standard to prove effectiveness of 
interventions and this is no less true when the goal is to show the real-world effectiveness of the 
intervention in learning healthcare systems. However, the standard approach to RCTs is often 
complicated by slow recruitment rates, limited generalisability, limited long term follow up, and 
high costs. The µ7ULDOVZLWKLQ&RKRUWV¶ design (formerly referred to as the 'cohort multiple RCT 
design'(14, 15)) was created to address these problems for when comparing an intervention of 
interest with a usual care control arm using an unmasked design.  
In the TwiCs design, a cohort of participants with the condition(s) of interest is recruited 
for a longitudinal cohort study.  At the time of recruitment into the cohort, the participants are 
given information about the process for their potential involvement in future intervention studies 
(i.e., TwiCs) and consent is obtained for potential future use of their data. A critical point, and 
one which varies from TwiCs to TwiCs, is whether this discussion also includes an explicit 
consent to be randomly assigned to control or intervention in unspecified future trials. Some 
implementations of TwiCs have given no specific information about future clinical trials (only 
general information about future use of their data in other studies) to the cohort participants(4, 
16) while others obtain consent (at initial recruitment into the cohort) regarding future 
randomization prior to TwiCs and use of data in future TwiCs(12, 17) as described further 
below.  
After randomization to any given trial within the cohort, additional consent to receive the 
intervention is obtained from participants who have been randomly assigned to the new 
intervention. Those assigned to the treatment as usual control arm do not provide any additional 
consent after randomization.   
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The TwiCs design has several advantages over standard RCT design. First, difficulty with 
recruitment is a common concern in RCTs. The TwiCs design takes advantage of the fact that 
recruitment into observational cohort studies is often easier and less selective. There is now 
evidence that recruitment for RCTs within such established cohorts can be highly efficient when 
compared to recruitment without such cohorts.(18)   
Second, disclosure of information and informed consent can be tailored to the needs of 
the participants (e.g., those not offered the new intervention are not burdened with information 
about the risks and potential benefits of trial intervention). Thus, the informed consent process is 
µSDWLHQWFHQWHUHG¶DQGµUHDOZRUOG¶LQLWVJRDOV²replicating, as much as is ethically feasible, the 
real world routine health care where clinicians provide patients with the information they need, 
at the time they need it.  This may in fact increase the autonomous decision-making by patient-
subjects by reducing some of the widely discussed challenges in the consent process, such as 
decisional burden, confusion and information overload.[If accepted, cite accompanying article on 
this topic.]  
Third, the design reduces some problems related to patient preferences in standard RCT 
designs. For instance, when a condition does not have highly effective interventions, the prospect 
of trying a new, if unproven, intervention is often an incentive for patients to enrol. In standard 
RCT designs, this often results in those randomized to the µtreatment as usual¶ arm dropping out 
or experiencing disappointment. But this does not occur in the TwiCs design.  
Another advantage of embedding RCTs within an established cohort is that periodic 
research data collection that is part of the longitudinal study can provide outcome data in 
addition to data from medical records.(10)   
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However, the TwiCs design does have limitations. It is only applicable to unmasked 
studies and requires (at leasWRQHµXVXDOFDUH¶FRQWURODUP; however, it is not unusual for 
pragmatic studies HPXODWLQJµUHDOZRUOG¶FRQGLWLRQVWRKDYHXQPDVNHGXVXDOFDUHFRQWURO
designs. TwiCs will also have the same limitations regarding potentially biased outcome 
reporting in unmasked studies.  Another limitation of TwiC design is the potential bias 
introduced by non-compliance in the intervention arm. This involves two issues.  
First, since in the traditional RCT design only those willing to try either arm are 
recruited, the two arms will be more comparable (assuming random dropouts in both arms) than 
in the TwiCs trial.  However, the traditional design is less pragmatic (less generalizable) and in 
the TwiCs design, added information can be gleaned from the behaviour of those in the 
intervention arm, regarding the acceptability and adherence rates of new treatments in the real 
world.  
Second, the loss of subjects in the intervention arm will also reduce power in intention to 
treat analysis. Again, however, there are additional relevant considerations that mitigate this 
limitation.  Because the drop outs in the control arm will be nil, the overall loss of power is less, 
with lower likelihood of biased estimate of true treatment effect, in the TwiCs analysis than in 
traditional designs.{van der Delden 2016} This can been shown using simulations to compare 
intention to treat analysis with instrumental variable (or Complier Average Causal Effect 
analysis) analysis.{van der Delden 2016}  However, if the non-compliance in the intervention 
arm is very high, the relative advantage of the TwiCs design may be lost.      
A brief background on RCT designs with consent following randomization  
The TwiCs design is a descendent of a family of older proposals variously known as 
³=HOHQGHVLJQ,´ ³UDQGRPL]HGFRQVHQW,´RU³SUH-UDQGRPL]DWLRQ´designs.(19) A brief history of 
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these proposals and their implementation illustrates some of their strengths and weaknesses and 
also helps to clarify how TwiCs is different from these earlier proposals.  
The original proposal for post-randomization consent, called a ³Zelen single-consent 
design,´ (named after the biostatistician who proposed it) was the simplest: patients were, 
without prior consent or knowledge, randomized between ³EHVWVWDQGDUG´ care (usual care) and 
an intervention.(19) Subjects assigned to the intervention were then asked for consent, while the 
others served as control subjects without their knowledge (thus the label µVLQJOH-FRQVHQW¶. 
Several advantages were proposed for the single-consent design.(19) It reduces the need for 
investigators to present, and patients to confront, stressful aspects of research participation, such 
as knowing that their treatment is going to be randomly chosen and being denied access to an 
experimental treatment. Further, single-consent designs might increase the efficiency of accrual, 
in part because patients (assigned to the intervention arm) might be more inclined to enroll 
knowing that they were guaranteed to receive the intervention. 
Zelen seems to have interpreted the US Federal research regulations to say that as long as 
research subjects UHFHLYHGRQO\³established and accepted methods necessary to meet [their] 
needs´LQIRUPHGFRQVHQWZDVQRWQHFHVVDU\(20) However, the Office of Protection from 
Research Risks (OPRR) eventually disagreed, and reprimanded the investigators of a study of 
neonates which used a Zelen single consent design for failing to obtain consent from parents of 
the control group neonates.(21)  
&ULWLFLVPRIWKHVLQJOHFRQVHQWSURFHGXUHOHGWRJUHDWHULQWHUHVWLQWKHµGRXEOH-consent 
=HOHQGHVLJQ¶LQZKLFKERWKWKHXVXDOFDUHDQGLQWHUYHQWLRQDUPVDUH approached for consent. In 
double-consent, in contrast to single-consent, all participants are at least informed that they are 
participating in research. However, in addition to the obvious difference from a traditional RCT 
9 
 
in obtaining consent after treatment assignment, Zelen double consent may include little or no 
information about the other arm of the trial, or indeed about the fact of randomization.(13)   
Trials using Zelen double and single consent designs have remained relatively 
uncommon²as of 2006, two reviews suggest that approximately 83 unique studies employing 
Zelen designs had been conducted.(22, 23) This relative unpopularity has no definitive 
explanation, but the experiences of investigators who have used post-randomization consent 
designs reveal both ethical and logistical problems. 
First, Zelen designs have attracted considerable ethical criticism.(24) Even though 
patients assigned to the control group undergo no harm, and might actually be spared burdens 
related to a traditional consent process, they might still reasonably expect to know that a new 
intervention is being tested for their condition and that they have been randomly assigned to a 
group whose data are used for comparison. The perception that information is being withheld has 
EHHQGHVFULEHGDVFDXVLQJDQµRXWFU\¶RIFRQFHUQDERXWWKHHWKLFVRIWKHHDUOLHVW=HOHQproposals, 
and subsequent modifications have not fully allayed these concerns.(25),27  As we note below, 
however, despite the 1990 reprimand by the OPRR, pragmatic RCTs are beginning to be 
conducted in the U.S. with post-randomization single-consent procedures with the apparent 
knowledge of the Office of Human Research Protections (the successor to the OPRR).(26) 
 Another problem with post-randomization consent is that it has not always proven to be 
as efficient as had been hoped.  Analysis of a post-randomization study has to be done as 
intention-to-treat, including patients who declined the intervention, which reduces study 
power.(25)  Post-randomization designs must improve accrual and withdrawal rates sufficiently 
to make up for this loss of power; these improvements are difficult to predict and are not 
guaranteed.(20)(27, 28) 
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Ethics of informed consent for TwiCs and regulatory implications 
 There are variations in practice when it comes to the content of the initial consent 
procedures regarding future embedded RCTs within the cohort. We first describe a consent 
procedure(29) which involves the greatest amount of disclosure regarding the elements of 
potential trials within a cohort.  We then discuss other variations.  
 TwiCs with pre-randomization broad consent about TwiCs elements.  In some 
jurisdictions, investigators implementing TwiCs have run into regulatory obstacles; this has led 
to the development of a consent model that includes explicit consent for some elements of future 
embedded trials.(29) At the time of recruitment into the cohort, subjects provide specific consent 
for the cohort study and also provide broad consent²µEURDG¶VLQFHWKHFRQVHQWcovers a range of 
unspecified future studies²that specifically includes information about randomizations for 
future TwiCs, for future contact if randomized to the intervention arm of TwiCs, and for use of 
their data in future TwiCs if randomized to the control arm. See Figure. 
 
 
 
 
 
FIGURE HERE 
 
For those whose data will serve as the control arm data, their participation in an 
embedded trial is exhausted by two elements: (a) being randomly selected as a control and (b) 
use of their data (usually collected from clinical medical records, or in some cases, from 
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measurements that are part of the longitudinal cohort study(10)) in the embedded trial.  Despite 
these elements, the entirety of their clinical experience will be decided by what their physicians 
consider to be the best care for them. When someone is randomized to the usual care arm, they 
have been randomized, not to a specific treatment, but to the ordinary interactions and decision-
making processes with his or her doctor; thus, how his or her care is determined and provided not 
disturbed at all.  Note that this is significantly different from randomly assigning a treatment 
(even if it is a commonly used one) where randomization determines the treatment itself, not the 
process for how it is determined.  Further, no additional research measures are needed; thus, no 
additional interactions or interventions of research are involved ZKHQWKHVHSHUVRQV¶GDWDDUH
used in TwiCs.  In sum, persons in the control arm receive care that is decided by usual clinical 
considerations and will have given consent to every element of their research participation.   
The lack of specificity in broad consent (i.e., broad permission for future use without 
specific consent for each use) has led to some prominent controversies in other domains of 
research, such as the much publicized Havasupai case in which the controversy centered around 
UHVHDUFKHUV¶XVHRIVDPSOHs and data that went beyond the disease domains of initial focus of the 
research.(30)  The difference in the TwiCs context is that unlike in most biobank-based research, 
the cohorts are disease-based (or at risk of it) as are the trials within them; thus, given the 
specificity of the domain of research, WKHUHLVOLWWOHULVNRIYLRODWLQJDQ\VXEMHFW¶VQRQ-welfare 
interests such as their cultural, religious, and moral commitments.(31)  For instance, for a person 
in a diabetes cohort who provides broad consent for use of their electronic health record and 
other data for evaluation of future diabetes treatments, there is little dangHURISDWLHQWV¶QRQ-
welfare interests (regarding the type of uses to which their data are put) being compromised.  
(However, it should be noted that if a cohort of interest were a very general one²for example, 
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one encompassing all patients in an integrated health delivery system²conducting TwiCs in 
such a cohort would require further ethical analysis regarding the content of the initial broad 
consent.) 
 Those randomized to the intervention arms of TwiCs will have given consent to be 
approached for enrolment in such trials. After being told that they have been randomly selected 
to an embedded clinical trial, they will then provide informed consent for the trial intervention. 
They would not be enrolled in an embedded trial unless they explicitly give consent after they 
are provided all the usually required elements of informed consent for an RCT.  Thus, everyone 
who enrolls in the intervention arm of the TwiCs will also have given informed consent to every 
aspect of their research participation in the TwiC. 
 TwiCs with only general pre-randomization discussion of future research.  Some 
TwiCs do not obtain explicit pre-randomization consent covering the possibility of future 
randomization and future contact for intervention studies. Consent is still obtained, but for 
unspecified future uses of their data (as part of the initial consent for enrolling in the cohort).(4, 
10, 16) The rationale is as follows.  For the intervention arm group of a future embedded trial, 
when they are randomized into the intervention arm and then subsequently contacted to be asked 
if they wish to enroll in the trial, it is not that different from someone in a clinic being 
DSSURDFKHGWRSDUWLFLSDWHLQDWUDGLWLRQDO5&77KHUHLVQRµFROGFRQWDFW¶LQYROYHGWKHVXEMHFWV
are aware that the clinic is a locus of clinical research, and they should not be surprised that they 
are being asked to consider participation in an RCT. 
 For the control arm, it might be argued that by enrolling in the cohort study (on, say, 
diabetes), their permission to the researchers to use their medical records and other data includes 
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a variety of future research uses, and this is sufficient to permit their use for comparison 
purposes in a TwiC testing an intervention to treat diabetes.       
 There are two potential objections to not employing pre-randomization consent that 
explicitly includes relevant elements about future embedded trials.  First, some may argue that 
randomization is a research procedure that always requires consent.  However, there are 
situations where randomization seems acceptable.  Suppose that a researcher randomly divides 
100 biobanked tissue samples into 2 groups, in order to conduct an experiment on the 
pathophysiology of diabetes.  Assume the diabetic donors of the tissues have provided broad 
consent for the use of the samples but the consent did not mention specific research studies (as is 
customary in broad consent) nor about methods used in future studies (e.g., randomization of 
samples).  Of course, in research studies where the randomization leads to any potential 
alterations in the way the subjects are treated (e.g., using an experimental intervention) always 
requires consent before such alterations are implemented but in this example, as in the control 
arm of the TwiCs study in question, there are no deviations from the usual way the subjects are 
treated.  And in the intervention arm, before any deviations from the usual are implemented, 
informed consent is obtained. 
 Second, it is plausible that some persons who are enrolled in a cohort who later find out 
that there are embedded randomized trials in that cohort may feel that the researchers could 
easily have made their plans for embedding trials in the cohort clearer from the beginning.  Some 
of these participants may feel that the researchers were not as transparent as they could have 
been, even while recognizing that the lack of transparency has no impact on their welfare 
(benefits and harms/burdens).  
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 Different people will have different moral intuitions about whether pre-randomization 
broad consent that specifically mentions elements about future embedded trials is ethically 
necessary. On one side of the argument is that there is a potential for mistrust due to the lack of 
transparency such that it may be not only ethically right but prudent to obtain an explicit consent 
to future embedded trials and randomization, especially if the burden of obtaining it is low. On 
the other side is the view that consent is not only unnecessary but could cause confusion (since 
the idea of broad consent to future randomization with asymmetric consequences for the 
participants could be a challenging set of concepts to digest), then it may be better to avoid it.  
We suspect that a part of the answer will rest on the particular features of the TwiCs²the nature 
of the cohort, the interventions involved, and the setting in which the study is done and the 
reasonable expectations that researchers might anticipate in the participants.   
 Implications for US regulations?  Although the use of TwiCs is gaining momentum, 
most of the activity has been in countries outside the United States.  Given the potential 
advantages of the TwiCs design, it may prove useful for US researchers as well. However, the 
regulations do differ among jurisdictions, especially regarding the issue of when it is permissible 
to deviate from the traditional informed consent procedures. 
 How might IRBs apply the US research regulations to TwiCs?  The task for the IRBs will 
be different depending on whether cohort studies employ pre-randomization broad consent for 
future embedded randomized trials in that cohort.  We begin with the assumption that pre-
randomization broad consent including explicit discussion of randomization is used. 
First, unlike recent debates in US in which the focus has been on whether traditional 
informed consent is necessary for pragmatic trials in learning health systems,(32, 33) TwiCs 
does not need to rely on waivers or alterations of informed consent.  As noted above, the 
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intervention arm participants, before consenting to the intervention in the TwiC, would have 
received all of the information that persons enrolling in traditional RCTs would receive.  The 
only difference is that the information is given (and consent for the intervention obtained) after 
randomization while consent for the randomization would have been given separately at the time 
of enrolment into the cohort. 
 The FRQWURODUPSDUWLFLSDQWV¶FRQVHQWZRXOGQRWEHZDLYHGRUDOWHUHGHLWKHU7KH\ZRXOG
have provided informed consent for the cohort study, and also given broad consent for 
randomization and for the use of their data for TwiCs.  Since those in the control group will have 
given consent to every element of their research participation, there is no need to invoke the 
criteria for waiver or alteration of consent in the Common Rule.   
 What about TwiCs that are proposed without a substantive pre-randomization broad 
consent?  The regulatory situation could involve the IRBs requiring the investigator to show that 
the waiver or alteration criteria in the US regulations are met. As we saw above, the intuition 
concerning the need for pre-randomization broad consent that specifies the elements of future 
embedded trials varies, and will likely vary among IRBs. It is possible that some IRBs will see 
the lack of transparency regarding randomization and future TwiCs as implying at least an 
alteration of informed consent, and therefore will require that such a proposal meet the several 
regulatory criteria for waiver or alteration of informed consent in 45CFR46.116:  (a) the research 
must be minimal risk; (b) the research would be impracticable to conduct without the waiver or 
aOWHUDWLRQFWKHSDUWLFLSDQWV¶rights or welfare would not be adversely affected by the waiver or 
alteration; (d) whenever appropriate, providing participants with additional pertinent information 
after participation.   
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 How might these criteria apply to studies that forgo substantive pre-randomization broad 
consent?  Although some TwiCs will be minimal risk, many will not be minimal risk; whether an 
IRB would or should analyze the risk-benefit issue separately for the intervention and the control 
arms is not clear.  In terms of the practicability of research criterion, it would be difficult to argue 
that the trial is impracticable without an alteration or waiver since there are examples of TwiCs 
that are being successfully conducted with substantive pre-randomization broad consent. And we 
have already noted that some people may see the lack of transparency about randomization into 
TwiCs as something that goes against their legitimate expectations²this could be interpreted by 
VRPHDVDWRGGVZLWKWKHFRQGLWLRQWKDWZDLYHURUDOWHUDWLRQQRWDGYHUVHO\DIIHFWVXEMHFWV¶ULJhts 
and welfare.(34)  Finally, an IRB would need to determine if debriefing after the embedded trial 
would be necessary for those assigned to the control arm.  Thus, some IRBs could require the use 
of substantive pre-randomization broad consent for TwiCs.   
It is, however, difficult to predict how this issue would finally be decided by the 
regulators. Of particular interest is a pragmatic clinical trial in the US involving approximately 
20,000 subjects comparing care management, skills training, and treatment as usual for the 
prevention of suicide attempts among outpatients who endorse suicidal thoughts on a routine 
clinical measure.(26)  According to the investigators, this study uses a modified Zelen design 
(control arm patients are unaware of the RCT; subjects in the intervention arms provide clinical 
consent to the interventions) that has been approved by IRBs of multiple institutions, and the 
LQYHVWLJDWRUVUHSRUWKDYLQJKHOG³H[WHQVLYHGLVFXVVLRQV´ZLWKWKH2IILFHRI+XPDQ5HVHDUFK
Protections. Thus, it appears that the study is deemed to pose no more than minimal incremental 
risk and also that it would have been impracticable to conduct without the waiver and alteration 
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of consent, despite what amounts to a single-consent Zelen design. However, the authors do not 
provide further details about how their IRBs made these determinations. 
Conclusion 
For conditions in which longitudinal cohort studies can be valuable (which likely 
includes most chronic conditions), recruiting and conducting multiple randomized trials within 
such cohorts provide significant scientific and ethical advantages over both traditional and stand-
alone Zelen designs.  With the increasing emphasis on pragmatic trials,(15, 35) investigators 
from many countries are now using this design. One of the main obstacles to its use is the 
concern over the ethics of obtaining informed consent for the embedded trials after randomizing 
the subjects and only from the intervention arm. Pre-randomization consent to cohort 
participation as well as, in some cases, to more explicit broad consent to elements of future 
TwiCs (including for randomization, and use of data specifically for TwiCs) mitigates this 
ethical concern. However, regulatory policies vary among jurisdictions and interpretations of 
those policies vary among research ethics committees. Investigators who hope to benefit from 
the scientific and practical advantages of the TwiCs design will need to clearly articulate its 
ethical and scientific strengths and limitations. 
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